Mene Pangalos, executive vice president of biopharmaceutical research and development for AstraZeneca , a British-Swedish multinational pharmaceutical and biopharmaceutical company, said that a vaccine for coronavirus could be available "anytime from September".
Preliminary findings from the Phase 1/2 trials of the University of Oxford's vaccine candidates show encouraging results. Tune in to the Explained podcast to find out . "This vaccine is meant to induce both, so it can attack the virus when it's circulating in the body, as well as attacking infected cells". According to the report , the experimental vaccine known as AZD1222 tested over 1,000 people in April.
The AZD1222 vaccine has been adapted from a common cold virus found in chimpanzees, with spike glycoprotein, a genetic material from the new coronavirus, added to it. Before a vaccine can be approved for mass production and global distribution, it has to go through three stages, sometimes four, of clinical trials in humans.
The scientists of Oxford had targeted a million doses of the vaccine by the end of September. "We do welcome the study and congratulate our colleagues at the Oxford University's General Institute and the Oxford Vaccine Group", said WHO's Health Emergencies Program Executive Director, Michael Ryan.
The participants either received the new COVID-19 vaccine (543 participants) or the meningococcal conjugate vaccine (534 people). Nucleic acid vaccines have emerged as ideal vaccine candidates that do not require pathogen culture or recombinant protein production.
Though younger children are less likely to spread COVID-19, they still transmit the disease at about 50% of the rate as adults. The latest coronavirus (COVID-19) numbers from Texas and LA County suggest mild weakness in the pandemic figures compared to the recent high statistics.